A importância da profilaxia do tromboembolismo venoso

Conteúdo do artigo principal

Marcelo Calil Burihan

Resumo

Em meio a pandemia do coronavirus, discutiu-se muito, em todo mundo, a respeito da profilaxia do tromboembolismo venoso (TEV) em pacientes internados ou não. Passada a pandemia, ou ao menos minimizada, devemos manter esse pensamento como um dos mais importantes durante e após a internação, independentemente do caso.



Detalhes do artigo

Como Citar
1.
Burihan MC. A importância da profilaxia do tromboembolismo venoso. HSJ [Internet]. 24º de novembro de 2020 [citado 18º de maio de 2024];10(4):1-. Disponível em: https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1070
Seção
EDITORIAL
Biografia do Autor

Marcelo Calil Burihan, Hospital Santa Marcelina. Faculdade Santa Marcelina. São Paulo, São Paulo, Brasil.

Professor da Faculdade de Medicina Santa Marcelina (FASM). Coordenador do Módulo Cirúrgico e Preceptor de Residência Médica em Cirurgia Vascular do Hospital Santa Marcelina. Membro Titular da Sociedade Brasileira de Angiologia e de Cirurgia Vascular (SBACV). Mestre pela Escola Paulista de Medicina da Universidade Federal de São Paulo (EPM/Unifesp). Diretor de publicações da SBACV (2020- 2021). Ex-presidente da SBACV-SP (2018-2019). Membro da Society for Vascular Surgery (SVS).

Referências

1. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3-14. https://doi.org/10.1007/s11239-015-1311-6 PMid:26780736 PMCid:PMC4715842
2. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007;167(14):1471-75. https://doi.org/10.1001/archinte.167.14.1471 PMid:17646600 PMCid:PMC2762787
3. Grosse SD, Nelson RE, Nyarko KA, et al. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016;137:3-10. https://doi.org/10.1016/j.thromres.2015.11.033 PMid:26654719 PMCid:PMC4706477
4. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756-64. https://doi.org/10.1160/TH07-03-0212 PMid:17938798
5. International Society on Thrombosis and Haemostasis [Internet]. Open your eyes to venous thromboembolism. [cited 2020 Nov 10] Avaiable from: https://www.worldthrombosisday.org/issue/vte/
6. Matchar DB, Mark DB. Strategies for incorporating resource allocation and economic considerations: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):132S-140S. https://doi.org/10.1378/chest.08-0671 PMid:18574263
7. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-94. Erratum in: Lancet. 2008;371(9628):1914. PMID: 18242412. https://doi.org/10.1016/S0140-6736(08)60202-0
8. NICE guideline [NG89]. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism [Internet]. London, UK: National Institute for Health and Care Excellence; 2018 Mar 21 [updated 2019 Aug 13; cited 2020 Nov 10]. Avaiable from: https://www.nice.org.uk/guidance/ng89
9. Kessler CM. The link between cancer and venous thromboembolism: a review. Am J Clin Oncol. 2009;32(4 Suppl):S3-7. https://doi.org/10.1097/coc.0b013e3181b01b17 PMID: 19654481.
10. Mulder FI, Candeloro M, Kamphuisen PW, Di Nisio M, Bossuyt PM, Guman N, et al.; CAT-prediction collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277-87. https://doi.org/10.3324/haematol.2018.209114 PMid:30606788 PMCid:PMC6545838
11. Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Lancet Oncol. 2016;17:e452-66. https://doi.org/10.1016/S1470-2045(16)30369-2